Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
Top Cited Papers
- 22 August 2004
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 10 (9), 942-949
- https://doi.org/10.1038/nm1093
Abstract
Regulatory T (Treg) cells mediate homeostatic peripheral tolerance by suppressing autoreactive T cells. Failure of host antitumor immunity may be caused by exaggerated suppression of tumor-associated antigen–reactive lymphocytes mediated by Treg cells; however, definitive evidence that Treg cells have an immunopathological role in human cancer is lacking. Here we show, in detailed studies of CD4+CD25+FOXP3+ Treg cells in 104 individuals affected with ovarian carcinoma, that human tumor Treg cells suppress tumor-specific T cell immunity and contribute to growth of human tumors in vivo. We also show that tumor Treg cells are associated with a high death hazard and reduced survival. Human Treg cells preferentially move to and accumulate in tumors and ascites, but rarely enter draining lymph nodes in later cancer stages. Tumor cells and microenvironmental macrophages produce the chemokine CCL22, which mediates trafficking of Treg cells to the tumor. This specific recruitment of Treg cells represents a mechanism by which tumors may foster immune privilege. Thus, blocking Treg cell migration or function may help to defeat human cancer.Keywords
This publication has 45 references indexed in Scilit:
- Regulatory T cells in transplantation toleranceNature Reviews Immunology, 2003
- Regulatory T cells under scrutinyNature Reviews Immunology, 2003
- Control of Regulatory T Cell Development by the Transcription Factor Foxp3Science, 2003
- Natural selection of tumor variants in the generation of “tumor escape” phenotypesNature Immunology, 2002
- Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-DioxygenaseScience, 2002
- The infusion of ex vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft-versus-host disease lethalityBlood, 2002
- Immunodominance and tumor escapeSeminars in Cancer Biology, 2002
- Regulatory T Cells in AutoimmmunityAnnual Review of Immunology, 2000
- Melanoma immunotherapy: new dreams or solid hopes?Immunology Today, 1996
- New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccinesMelanoma Research, 1996